195 related articles for article (PubMed ID: 38059214)
1. Trends in deep vein thrombosis prophylaxis after total hip arthroplasty: 2016 to 2021.
Moore MC; Dubin JA; Bains SS; Hameed D; Nace J; Delanois RE
J Orthop; 2024 Feb; 48():77-83. PubMed ID: 38059214
[TBL] [Abstract][Full Text] [Related]
2. Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty.
Bawa H; Weick JW; Dirschl DR; Luu HH
J Am Acad Orthop Surg; 2018 Oct; 26(19):698-705. PubMed ID: 30153117
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?
Bala A; Murasko MJ; Burk DR; Huddleston JI; Goodman SB; Maloney WJ; Amanatullah DF
Hip Int; 2020 Sep; 30(5):564-571. PubMed ID: 30990095
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty.
Piple AS; Wang JC; Kang HP; Mills ES; Mayfield CK; Lieberman JR; Christ AB; Heckmann ND
J Arthroplasty; 2023 Aug; 38(8):1613-1620.e4. PubMed ID: 36805121
[TBL] [Abstract][Full Text] [Related]
5. Trends in Deep Vein Thrombosis Prophylaxis After Total Knee Arthroplasty: 2016 to 2021.
Dubin JA; Bains SS; Hameed D; Remily EA; Moore MC; Mont MA; Nace J; Delanois RE
J Arthroplasty; 2024 Feb; ():. PubMed ID: 38325530
[TBL] [Abstract][Full Text] [Related]
6. Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Bala A; Huddleston JI; Goodman SB; Maloney WJ; Amanatullah DF
Clin Orthop Relat Res; 2017 Sep; 475(9):2205-2213. PubMed ID: 28569372
[TBL] [Abstract][Full Text] [Related]
7. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
Runner RP; Gottschalk MB; Staley CA; Pour AE; Roberson JR
J Arthroplasty; 2019 Apr; 34(4):729-734. PubMed ID: 30685257
[TBL] [Abstract][Full Text] [Related]
8. Comparison of postoperative complications after total hip arthroplasty among patients receiving aspirin, enoxaparin, warfarin, and factor Xa inhibitors.
Agaba P; Kildow BJ; Dhotar H; Seyler TM; Bolognesi M
J Orthop; 2017 Dec; 14(4):537-543. PubMed ID: 28878512
[TBL] [Abstract][Full Text] [Related]
9. Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial.
Ren Y; Cao SL; Li Z; Luo T; Feng B; Weng XS
Chin Med J (Engl); 2021 Jan; 134(2):164-172. PubMed ID: 33410616
[TBL] [Abstract][Full Text] [Related]
10. Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis.
Farey JE; An VVG; Sidhu V; Karunaratne S; Harris IA
Orthop Traumatol Surg Res; 2021 Feb; 107(1):102606. PubMed ID: 32631716
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study.
Yhim HY; Lee J; Lee JY; Lee JO; Bang SM
PLoS One; 2017; 12(5):e0178214. PubMed ID: 28542415
[TBL] [Abstract][Full Text] [Related]
12. A risk-stratified approach to venous thromboembolism prophylaxis with aspirin or warfarin following total hip and knee arthroplasty: A cohort study.
Johnson SA; Jones AE; Young E; Jennings C; Simon K; Fleming RP; Witt DM
Thromb Res; 2021 Oct; 206():120-127. PubMed ID: 34455129
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Symptomatic Venous Thromboembolism (VTE) in 8,885 Elective Total Hip Arthroplasty Patients Receiving Post-operative Aspirin VTE Prophylaxis.
Coveney EI; Hutton C; Patel N; Whitehouse SL; Howell JR; Wilson MJ; Hubble MJ; Charity J; Kassam AM
Cureus; 2023 Mar; 15(3):e36464. PubMed ID: 37090282
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of aspirin and enoxaparin for venous thromboembolism prophylaxis after total hip and knee arthroplasty: a systematic review.
Nadi S; Vreugdenburg TD; Atukorale Y; Ma N; Maddern G; Rovers M
ANZ J Surg; 2019 Oct; 89(10):1204-1210. PubMed ID: 30989803
[TBL] [Abstract][Full Text] [Related]
16. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
[TBL] [Abstract][Full Text] [Related]
17. Thromboprophylaxis of Patients Submitted to Total Hip and Knee Arthroplasty: A Cost-Effectiveness Assessment From the Perspective of the Brazilian National Health System.
de Brito AFS; Brito NC; Tanaka SKT; Ferreira VL; Ferreira Júnior ABS; Riveros BS; Nita ME
Value Health Reg Issues; 2022 Sep; 31():111-118. PubMed ID: 35640463
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
Trkulja V; Kolundzic R
Croat Med J; 2010 Apr; 51(2):113-23. PubMed ID: 20401953
[TBL] [Abstract][Full Text] [Related]
19. Time to Venous Thromboembolism Events Following Total Hip Arthroplasty: A Comparison Between Aspirin and Warfarin.
Shohat N; Goel R; Ludwick L; Parvizi J
J Arthroplasty; 2022 Jun; 37(6):1198-1202.e1. PubMed ID: 35149168
[TBL] [Abstract][Full Text] [Related]
20. Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.
; Sidhu VS; Kelly TL; Pratt N; Graves SE; Buchbinder R; Adie S; Cashman K; Ackerman I; Bastiras D; Brighton R; Burns AWR; Chong BH; Clavisi O; Cripps M; Dekkers M; de Steiger R; Dixon M; Ellis A; Griffith EC; Hale D; Hansen A; Harris A; Hau R; Horsley M; James D; Khorshid O; Kuo L; Lewis P; Lieu D; Lorimer M; MacDessi S; McCombe P; McDougall C; Mulford J; Naylor JM; Page RS; Radovanovic J; Solomon M; Sorial R; Summersell P; Tran P; Walter WL; Webb S; Wilson C; Wysocki D; Harris IA
JAMA; 2022 Aug; 328(8):719-727. PubMed ID: 35997730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
